ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01591447
Recruitment Status : Completed
First Posted : May 4, 2012
Last Update Posted : March 3, 2017
Sponsor:
Information provided by (Responsible Party):
Cempra Inc

Brief Summary:
To determine the safety and efficacy of a single dose of solithromycin (CEM-101) for the treatment of uncomplicated urogenital gonorrhea.

Condition or disease Intervention/treatment Phase
Uncomplicated Urogenital Gonorrhea Drug: solithromycin Drug: Solithromycin (CEM-101) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study to Evaluate the Efficacy and Safety of a Single-Dose of Oral CEM-101 in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea
Study Start Date : May 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Gonorrhea

Arm Intervention/treatment
Experimental: Solithromycin (CEM-101)
A single oral dose of 1200 mg solithromycin
Drug: solithromycin
A single oral dose of 1200 mg solithromycin (CEM-101)

Experimental: Solithromycin 1000 mg
A single oral dose of 1000 mg solithromycin
Drug: Solithromycin (CEM-101)
A single oral dose of 1000 mg solithromycin




Primary Outcome Measures :
  1. The bacterial eradication rate, as measured by conversion from positive Neisseria gonorrhoeae baseline urethral or cervical culture to negative [ Time Frame: 3 to 9 days after study drug dosing ]

Secondary Outcome Measures :
  1. Safety and tolerability of a single oral dose of CEM-101 in adult patients with uncomplicated urogenital gonorrhea [ Time Frame: One day after study drug dosing, and 3 to 9 days after study drug dosing ]
    Adverse event reporting, clinical laboratory evaluations

  2. The bacterial eradication of rectal or pharyngeal gonococcal infection (if positive culture at baseline) [ Time Frame: 3 to 9 days after study drug dosing ]
  3. Eradication or persistence of N. gonorrhoeae nucleic acid (as measured by positive NAAT assay) from urethral and cervical specimens [ Time Frame: 3 to 9 days after study drug dosing ]
  4. Eradication or persistence of Chlamydia trachomatis nucleic acid (as measured by positive NAAT assay) from urethral and cervical specimens [ Time Frame: 3 to 9 days after study drug dosing ]
  5. In vitro minimum inhibitory concentrations (MICs) of gonococcal strains isolated [ Time Frame: Baseline and (if applicable) 3 to 9 days after study drug dosing ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Evidence of a urogenital gonococcal infection (prior culture, NAAT test, Gram stain, sexual contact)
  2. Willing to abstain from anal, oral, or vaginal sexual intercourse or use condoms until study completion.
  3. Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test at enrollment.

Exclusion Criteria:

  1. Confirmed, or suspected, complicated or systemic gonococcal infections such as pelvic inflammatory disease, arthritis, or endocarditis.
  2. Known HIV, chronic hepatitis B, or hepatitis C infection.
  3. Known concomitant infection which would require additional systemic antibiotics.
  4. Use of systemic or intravaginal antibiotics within 30 days prior to study drug administration.
  5. Current use of corticosteroid drugs or other immunosuppressive therapy.
  6. Cytotoxic chemotherapy or radiation therapy within the previous 3 months.
  7. Known significant renal, hepatic, or hematologic impairment.
  8. History of intolerance or hypersensitivity to macrolide antibiotics.
  9. Any concomitant condition that, in the opinion of the Investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy and follow-up could be completed (e.g., life expectancy <30 days).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01591447


Locations
United States, Alabama
Jefferson County Department of Health
Birmingham, Alabama, United States, 35233
United States, Washington
Harborview STD Clinic
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Cempra Inc
Investigators
Principal Investigator: Edward W Hook, MD University of Alabama at Birmingham

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Cempra Inc
ClinicalTrials.gov Identifier: NCT01591447     History of Changes
Other Study ID Numbers: CE01-202
First Posted: May 4, 2012    Key Record Dates
Last Update Posted: March 3, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Gonorrhea
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Sexually Transmitted Diseases
Infection
Genital Diseases, Male
Genital Diseases, Female